GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P, Stichel D, Sill M, Schrimpf D, Sturm D, Selt F, Ecker J, Kazdal D, Miele E, Kranendonk MEG, Tops BBJ, Kohlhof-Meinecke P, Beschorner R, Kramm CM, Hasselblatt M, Reifenberger G, Capper D, Wesseling P, Stenzinger A, Milde T, Korshunov A, Witt O, Pfister SM, Wick W, von Deimling A, Jones DTW, Sahm F.
Sievers P, et al. Among authors: witt o.
Acta Neuropathol. 2021 Dec;142(6):1065-1069. doi: 10.1007/s00401-021-02369-1. Epub 2021 Sep 18.
Acta Neuropathol. 2021.
PMID: 34536122
Free PMC article.
No abstract available.